|
Daily Medical Update
Prostate cancer screening
Wednesday, September 02, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The Cochrane database of systematic reviews (2026) - Meta-Analysis
Key Findings
- Screening likely reduced prostate cancer-specific mortality (rate ratio 0.87, 95% CI 0.80-0.95), corresponding to about 2 fewer deaths per 1,000 men from a baseline risk of 16 per 1,000.
- Screening increased prostate cancer diagnoses (rate ratio 1.30, 95% CI 1.27-1.34) and localized disease diagnoses (RR 1.53, 95% CI 1.48-1.59), while metastatic diagnoses may have decreased (RR 0.65, 95% CI 0.59-0.71).
📋 Practice Implication: Use PSA screening as an individualized shared decision; the possible mortality benefit must be weighed against increased diagnosis and uncertain downstream harms.
|
European urology (2025) - Randomized Controlled Trial
Key Findings
- An MRI-first pathway produced higher biopsy rates (10.8% vs 5.2%) and clinically significant cancer detection (4.6% vs 1.8%) than PSA-triggered MRI; the relative risk for significant cancer detection was 2.6 (95% CI 1.1-6.1; p=0.05).
- MRI-first improved grade selectivity (1.89 vs 1.75), biopsy efficiency (0.74 vs 0.54), and biopsy avoidance (23.1 vs 11.9); no serious adverse events were recorded.
📋 Practice Implication: A contrast-free MRI-first pathway may improve early detection and benefit-harm balance, but the single-center, short-follow-up design supports cautious adoption with local validation.
|
The Journal of urology (2026) - Practice Guideline
Key Findings
- The 2026 amendment revised evidence- and consensus-based guidance covering screening, imaging and biomarker use, initial and repeat biopsy, and biopsy technique, improving the framework for early-detection decisions.
- The update specifically revised evidence strength for MRI in biopsy-naïve patients and biopsy techniques; biomarker and atypical small acinar proliferation recommendations were also revised to improve diagnostic yield while minimizing harm.
📋 Practice Implication: Clinicians should align screening referrals and diagnostic workups with the updated AUA/SUO framework, recognizing that MRI, biomarkers, and biopsy strategies remain an evolving standard.
|
International journal of cancer (2026) - Comparative Study
Key Findings
- Compared with fixed four-year PSA screening, PSA-based intervals reduced PSA tests by 21%; adding a risk calculator reduced overdiagnosis by 10% and required 36% fewer MRIs than an MRI-only protocol.
- The full EAU protocol maintained equal prostate cancer mortality at 200 deaths per 10,000 men while reducing biopsies and overdiagnosis relative to the ERSPC-based approach.
📋 Practice Implication: Risk-adapted PSA intervals combined with a risk calculator and MRI can improve screening efficiency while preserving modeled mortality benefit, subject to implementation resources.
|
European urology (2026) - Systematic Review
Key Findings
- For clinically significant cancer at the patient level, bpMRI sensitivity differed from mpMRI by -2.3% (95% CI -4.1% to -0.5%) and specificity by +1.8% (95% CI -0.4% to +4.0%), meeting the prespecified noninferiority margin.
- At the lesion level, bpMRI was noninferior for specificity but not sensitivity, so improved lesion-level sensitivity was not established.
📋 Practice Implication: bpMRI can be considered as a streamlined patient-level diagnostic option when image quality is assured, while lesion-level sensitivity limitations argue for quality control and selective use.
|
|
💡
Summary
The updated evidence suggests PSA screening probably produces a small reduction in prostate cancer-specific mortality, but also increases prostate cancer diagnoses and raises continuing concerns about overdiagnosis and downstream harms. MRI-first, biparametric MRI, and risk-adapted protocols may improve clinically significant cancer detection or screening efficiency, while current AUA/SUO guidance emphasizes coordinated use of MRI, biomarkers, and biopsy strategies.
|
|